1800047-00-0

1800047-00-0 structure

Name: Lanraplenib succinate
Chemical Name: Lanraplenib succinate
CAS Number: 1800047-00-0
Molecular Formula: C₂₃H₂₅N₉O_.3/₂C₄H₆O₄
Molecular Weight: 620.64
Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK Syk
Create Date: 2019-12-07 23:51:54
Modify Date: 2024-01-17 15:09:07
Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate (GS-9876 succinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans[1][2][3].

Name	Lanraplenib succinate

Description	Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate (GS-9876 succinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans[1][2][3].
Related Catalog	Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Syk
Target	IC50: 9.5 nM (SYK)[1]
In Vitro	Lanraplenib succinate (GS-9876 succinate) inhibits anti-IgM stimulated phosphorylation of AKT, BLNK, BTK, ERK, MEK, and PKCδ in human B cells with EC50 values of 24-51 nM. Lanraplenib monosuccinate inhibits anti-IgM mediated CD69 and CD86 expression on B-cells (EC50=112±10 nM and 164±15 nM, respectively) and anti-IgM /anti-CD40 co-stimulated B cell proliferation (EC50=108±55 nM). In human macrophages, Lanraplenib succinate inhibits IC-stimulated TNFα and IL-1β release (EC50=121±77 nM and 9±17 nM, respectively)[1]. Lanraplenib succinate (GS-9876 succinate) inhibits glycoprotein VI (GPVI)-induced phosphorylation of linker for activation of T cells and phospholipase Cγ2, platelet activation and aggregation in human whole blood, and platelet binding to collagen under arterial flow[2].
References	[1]. Di Paolo J, et al. FRI0049 Preclinical Characterization of GS-9876, A Novel, Oral SYK Inhibitor That Shows Efficacy in Multiple Established Rat Models of Collagen-Induced Arthritis.Annals of the Rheumatic Diseases 2016;75:443-444. [2]. Clarke AS, et al. Effects of GS-9876, a novel spleen tyrosine kinase inhibitor, on platelet function and systemic hemostasis. Thromb Res. 2018 Oct;170:109-118. [3]. Kivitz AJ, et al. GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients with Active Rheumatoid Arthritis: Safety, Tolerability and Efficacy Results of a Phase 2 Study [abstract]. Arthritis Rheumatol.2018; 70 (suppl 10).

Molecular Formula	C₂₃H₂₅N₉O_.3/₂C₄H₆O₄
Molecular Weight	620.64

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

1800047-00-0	1800046-97-2
1800046-95-0	13415-07-1
5634-40-2	83784-20-7
16090-09-8	106-65-0
106635-81-8	158930-09-7
1795784-46-1	1798827-45-8
1873425-65-0	1822334-01-9
1824019-40-0	1422971-59-2
2062051-28-7	1823320-50-8
1598181-49-7	1602194-44-4